期刊文献+

多中心风湿免疫病生物样本库标准化建设与意义 被引量:2

Standardization construction and significance of multicenter rheumatic immune disease biological sample bank
下载PDF
导出
摘要 目的探讨风湿免疫病样本的采集和保存、以及生物样本库的建立和信息化管理方法。方法以深圳市福田区风湿病专科医院为依托,采用相关技术收集各类样本,包括患者的血液、尿液、DNA等;用-80℃冰箱冷冻、液氮罐等保存样本;同时建立信息系统用于风湿免疫病生物样本库的规范管理,包括样本存放位置、样本使用、实验结果分析、综合查询、质量控制、样本废除管理等;并通过云共享实现多中心生物样本库管理。结果自2014年12月起筹建风湿免疫病生物样本库,截至2019年7月31日,已经实现了对736人次风湿免疫病和52人次健康对照者样本的收集和信息化管理;在生物样本库建立和维护的过程中,从样本入库、保存、出库等多个环节实现了对样本的标准化技术质量控制。结论通过建立院级风湿免疫病生物样本库与远程云共享生物样本库平台,将临床样本高质量地保存下来,为基础、临床研究提供丰富宝贵的资源,为研究的可持续发展提供保障。风湿免疫病生物样本库的建立同时也使疾病样本的储存系统化和规范化,对相关疾病早期诊断、新药研发、基因检测、遗传病发病机制等领域均有重要作用,同时也为转化医学提供基础平台。 Objective To research the collection,preservation of rheumatic immune disease specimens and establishment of biobank and the management information.Methods Based on the Shenzhen Futian Hospital for Rheumatic Diseases,and used relevant techniques to various samples,including blood,urine,DNA and other types of patients;-80℃refrigerator freezing,liquid nitrogen tanks,etc.We established a set of information system for the standardized management of the biobank of rheumatic diseases,including specimen storage,specimen using,experimental results,comprehensive query,quality control,specimen abolition management,etc.Multi-center biological sample library management was built through cloud sharing.Results Since December 2014,a database of rheumatoid immune diseases has been prepared.As of July 31,2019,736 rheumatoid immune diseases samples and 52 healthy control samples had been achieved.We standardized biobank through quality control of the samples.Conclusion Our hospital has established a high-quality clinical sample by establishing a hospital-level rheumatoid disease biobank and a novel way with remote cloud sharing biobank platform,providing valuable resources for basic and clinical research,providing sustainable guarantees for research.The establishment of a biobank for rheumatic diseases also makes the storage and standardization of disease samples systematic,and plays an important role in the early diagnosis with related diseases,new drug development,genetic testing,genetic pathogenesis,etc.It also provides a basic platform for translational medicine.
作者 曾惠琼 丁慧华 熊力群 唐元家 孙华麟 康晓楠 张跃 叶志中 ZENG Huiqiong;DING Huihua;XIONG Liqun;TANG Yuanjia;SUN Hualin;KANG Xiaonan;ZHANG Yue;YE Zhizhong(Department of Rheumatology,Futian District Rheumatism Hospital,Shenzhen Guangdong 518000,China;Department of Rheumatology,Renji Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai 200025,China)
出处 《转化医学杂志》 2019年第5期282-286,共5页 Translational Medicine Journal
基金 深圳市医疗卫生三名工程(SZSM2016020287) 2017年深圳市卫生计生系统科研项目(SZXJ2017040) 2018福田区卫生计生科研项目(FTWS2018067) 2018深圳市科创委布局项目(JCYJ20180504170414637)
关键词 风湿免疫病 生物样本库 标准化 Rheumatic disease Biobank Standardization
  • 相关文献

参考文献5

二级参考文献48

  • 1季加孚.北京大学临床肿瘤学院标本库的建设[J].北京大学学报(医学版),2005,37(3):329-330. 被引量:81
  • 2邱均平,余以胜,邹菲.内容分析法的应用研究[J].情报杂志,2005,24(8):11-13. 被引量:57
  • 3US Department of Health and Human Services, Food and Drug Administration. Challenge and opportunity on the critical path to new medical products [ EB/OL]. (2004-03-16). http://www. fda. gov/ScienceResearch/SpecialTopics/CriticalPathIntiative/Cri- ticalPathOpportunitiesReports/. UCM0771262. htm. 被引量:1
  • 4US Department of Health and Human Services, Food and Drug Administration. Critical path opportunities report [ EB/OL ]. (2006-03). http ://www. fda. gov/ScienceResearch/SpecialTopics/ CriticalPathIntiative/CriticalPathOpportunitiesReports/. UCM077- 254. pdf. 被引量:1
  • 5Vaught J, Rogers J, Myers K, et al. An NCI perspective on creating sustainable biospecimen resources. J Natl Cancer Inst Monogr, 2011,42:1-7. 被引量:1
  • 6Vgv6ri , Welinder C, Lindberg H, et al. Biobank resources for future patient care:developments, principles and concepts. J Clin Bioinforma, 2011,1:24. 被引量:1
  • 7Merrero JA, Henley KS. The role of serum biomarkers in hepatocellular carcinoma surveillance. Gastroenterol Hepatol, 2011,7:821-823. 被引量:1
  • 8Franco JR, Simarro PP, Diarra A, et al. The human African trypanosomiasis specimen biobank: a necessary tool to support research of new diagnostics. PLoS Negl Trop Dis, 2012,6:e1571. 被引量:1
  • 9DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new esimates of drug development costs. J Health (NY) Econ, 2003,22 : 151-185. 被引量:1
  • 10Khleif SN, Doroshow JH, Hait WN, et al. AACR-FDA-NCI Cancer Biomarkers Collaborative Consensus Report:advancing the use of biomarkers in cancer drug development. Clin Cancer Res, 2010,16:3299-3318. 被引量:1

共引文献61

同被引文献20

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部